Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 8
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
Authors Wiwanitkit V
Received 18 April 2012
Accepted for publication 17 May 2012
Published 22 June 2012 Volume 2012:8 Pages 323—328
DOI https://doi.org/10.2147/TCRM.S30139
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Viroj Wiwanitkit1–3
1Wiwanitkit House, Bang Khae, Bangkok, Thailand; 2Hainan Medical University, Haikou, Hainan, People's Republic of China; 3Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, Nigeria
Abstract: Leishmaniasis is an important vector-borne disease, and it is classified as one of the most important tropical fly-borne infections. This disease can cause two types of clinical manifestations: cutaneous forms and visceral forms. Visceral leishmaniasis, which is also called kala-azar, is a very serious infection that can be fatal. The management of visceral leishmaniasis requires informed diagnostic and therapeutic approaches. Continuous research and development regarding the treatment of visceral leishmaniasis had led to many improvements. Paromomycin is a relatively new antibiotic drug that has been used for the treatment of visceral leishmaniasis for several years. This article reviews and discusses the use of paromomycin for visceral leishmaniasis therapy.
Keywords: visceral, leishmaniasis, paromomycin
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.